AETHLON MEDICAL INC (AEMD): Entry into a Material Definitive Agreement
AETHLON MEDICAL INC (AEMD) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 6 aethlon_ex1001.htm FORM OF SECURITIES PURCHASE AGREEMENT Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “ Agreement ”) is dated as of July 6, 2026, between Aethlon Medical, Inc., a Nevada corporation (the “ Company ”), and each purch
How this was made
The 30-second read
Why it matters
This type of filing typically precedes or accompanies a capital raise. Traders often reassess dilution, warrant overhang, and liquidity/float changes once the final terms (proceeds and share counts) are known.
Market read
New financing documentation can drive immediate repricing due to dilution and warrant overhang, especially for micro/small-cap issuers.
What to watch
Key missing details in the excerpt include total gross proceeds, number of shares/warrants, conversion or exercise mechanics, and whether closing has occurred; those determine dilution magnitude and trading impact.
Background
The article is an SEC Form 8-K reporting entry into a material definitive agreement, with Exhibit 10.1 containing a securities purchase agreement and warrant terms.
Ticker impact
Aethlon Medical entered a material definitive agreement, filing an 8-K with a securities purchase agreement and warrant terms.
Near-term downside or volatility risk from potential dilution, with direction depending on deal size and closing terms not shown in the excerpt.
The filing confirms a financing agreement exists, but the provided text is largely boilerplate and does not include total proceeds, share count, or closing outcome.
Market effects
For small-cap medical device/biotech issuers, new warrant financings can signal ongoing capital needs and affect sector risk appetite.
Primarily US small-cap sentiment; limited direct regional spillover implied.
Low global relevance; this is company-specific capital-raise documentation.
Counterpoint
If the financing is structured with favorable pricing or includes pre-funded warrants that reduce future cash burn, the market reaction could be muted or even positive.
Key entities
- companyAethlon Medical, Inc.
Subject of the 8-K, entering a securities purchase agreement with purchasers and issuing common and warrant instruments.
